656 related articles for article (PubMed ID: 10553165)
21. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
22. Guidelines for the administration of amifostine.
Schuchter LM
Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
[TBL] [Abstract][Full Text] [Related]
23. Future development of amifostine in cancer treatment.
Alberts DS; Bleyer WA
Semin Oncol; 1996 Aug; 23(4 Suppl 8):90-9. PubMed ID: 8783674
[TBL] [Abstract][Full Text] [Related]
24. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
25. Future directions in gynecologic cancer.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
[TBL] [Abstract][Full Text] [Related]
26. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
27. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
28. Amifostine in clinical oncology: current use and future applications.
Koukourakis MI
Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
[TBL] [Abstract][Full Text] [Related]
29. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
30. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
31. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
32. [Amifostine: current and future applications in cytoprotection].
Lenoble M
Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
34. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment with cytoprotective agents and radiotherapy.
Winczura P; Jassem J
Cancer Treat Rev; 2010 May; 36(3):268-75. PubMed ID: 20044209
[TBL] [Abstract][Full Text] [Related]
36. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
37. Amifostine: potential for clinically useful cytoprotection.
Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
[TBL] [Abstract][Full Text] [Related]
38. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
39. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
40. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
